News

Sarepta Therapeutics (NASDAQ: SRPT) saw a lot of love from the market as the trading week kicked off on Monday. Investors pushed the stock almost 5% higher in price, a move due in no small part to

Shares of Coherus (NASDAQ: CHRS) rallied as much as 21.7% early Monday, then gave up its gains to trade up around 2.4% as of 2:40 p.m. ET. This occurred after the company announced an agreement to

Vertex Pharmaceuticals (NASDAQ: VRTX) has been one of the fastest-growing healthcare companies in recent years. Its products have made it a leader in cystic fibrosis (CF) treatment and it has been

Vertex Pharmaceuticals (NASDAQ: VRTX) has been one of the fastest-growing healthcare companies in recent years. Its products have made it a leader in cystic fibrosis (CF) treatment and it has been

Vertex Pharmaceuticals (NASDAQ: VRTX) has been one of the fastest-growing healthcare companies in recent years. Its products have made it a leader in cystic fibrosis (CF) treatment and it has been

The new year is here, and for many, it's a fresh opportunity to set financial goals and find fresh stocks to consider adding to a portfolio. The types of stocks you gravitate toward will broadly be

The new year is here, and for many, it's a fresh opportunity to set financial goals and find fresh stocks to consider adding to a portfolio. The types of stocks you gravitate toward will broadly be

Right now marks an exciting moment for CRISPR Therapeutics (NASDAQ: CRSP) and its investors. The biotech company has reached three milestones in just a couple of months. First, back in November, the

Right now marks an exciting moment for CRISPR Therapeutics (NASDAQ: CRSP) and its investors. The biotech company has reached three milestones in just a couple of months. First, back in November, the

Right now marks an exciting moment for CRISPR Therapeutics (NASDAQ: CRSP) and its investors. The biotech company has reached three milestones in just a couple of months. First, back in November, the

Looking for stocks with explosive growth potential? The biotech industry is an excellent place to start. Small drugmakers often see their shares skyrocket following positive clinical or regulatory

You've probably heard that bleeding-edge biotechs like Intellia Therapeutics (NASDAQ: NTLA) and CRISPR Therapeutics (NASDAQ: CRSP) are working hard to develop gene therapies to cure intractable

COVID-19 has been especially rough for Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) investors over the last couple of years. Shares of both drugmakers have plunged as the demand for their

COVID-19 has been especially rough for Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) investors over the last couple of years. Shares of both drugmakers have plunged as the demand for their

While the market bounced back last year, some stocks failed to keep pace with broader equities. That was the case with pharma giant AbbVie (NYSE: ABBV) and e-commerce specialist Etsy (NASDAQ: ETSY)

It's hard for me to pick my top favorite in many categories. Whether talking about actors, athletes, songs, singers, movies, or TV shows, I find it difficult to single one out as the best.

This

It's hard for me to pick my top favorite in many categories. Whether talking about actors, athletes, songs, singers, movies, or TV shows, I find it difficult to single one out as the best.

This

It's hard for me to pick my top favorite in many categories. Whether talking about actors, athletes, songs, singers, movies, or TV shows, I find it difficult to single one out as the best.

This

Abbott Laboratories (NYSE: ABT) and AbbVie (NYSE: ABBV) share a common past. About a decade ago, Abbott spun out its pharmaceuticals business into a separate company to create AbbVie. Since then

One of the most important companies during the peak of the COVID-19 pandemic was pharmaceutical giant Pfizer (NYSE: PFE). The company's breakthrough vaccine helped pave the way for a post-pandemic

One of the most important companies during the peak of the COVID-19 pandemic was pharmaceutical giant Pfizer (NYSE: PFE). The company's breakthrough vaccine helped pave the way for a post-pandemic

It's been a few years since the average investor behaved as if no challenge was too tough for America's biopharmaceutical industry. In turn, shares of gene-editing startup Editas Medicine (NASDAQ:

It's been a few years since the average investor behaved as if no challenge was too tough for America's biopharmaceutical industry. In turn, shares of gene-editing startup Editas Medicine (NASDAQ:

It's been a few years since the average investor behaved as if no challenge was too tough for America's biopharmaceutical industry. In turn, shares of gene-editing startup Editas Medicine (NASDAQ: